Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the
vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated …

Real-time cell analysis (RTCA) enables high-throughput, quantitative kinetic measurements
of cytopathic effect (CPE) in virus-infected cells. Here, we detail a RTCA approach for …

Streptococcus pneumoniae persists as a leading cause of bacterial pneumonia despite the
widespread use of polysaccharide-based vaccines. The limited serotype coverage of current …

Monoclonal antibodies against the Ebola virus (EBOV) surface glycoprotein are effective
treatments for EBOV disease. Antibodies targeting the EBOV glycoprotein (GP) head epitope …

Ebola virus (EBOV), one member of the family Filoviridae, can causes hemorrhagic fever
and other severe diseases in humans with a high mortality rate (25–90%). Until recently …

The filoviruses, including ebolaviruses and marburgviruses, are among the world's deadliest
pathogens. As the only surface-exposed protein on mature virions, their glycoprotein GP is …

Introduction Due to their faithful recapitulation of human disease, nonhumanprimates
(NHPs) are considered the gold standard for evaluating drugs against Ebolavirus and other …

Adaptive immunity to viral infections requires time to neutralize and clear viruses to resolve
infection. Fast growing and pathogenic viruses are quickly established, are highly …

Filoviruses are negative-sense single-stranded RNA viruses often associated with severe
and highly lethal hemorrhagic fever in humans and nonhuman primates, with case fatality …

Monoclonal antibodies (mAbs) have proven effective for the treatment of ebolavirus infection
in humans, with two mAb-based drugs Inmazeb™ and Ebanga™ receiving FDA approval in …